Update on the oncologic and obstetric outcomes of medroxyprogesterone acetate treatment for atypical endometrial hyperplasia and endometrial cancer
Journal of Obstetrics and Gynaecology Research · 2024-09 · 50 (9) · 1614-1621
DOI: 10.1111/jog.16038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, online erschienen am 02.08.2024. Verfasst von Satoshi Tamauchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Medroxyprogesterone Acetate, Endometrial Hyperplasia, Endometrial Neoplasms, Fertility Preservation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Aims
To evaluate the safety and effectiveness of high‐dose oral medroxyprogesterone acetate (MPA) therapy as a fertility‐sparing treatment for patients diagnosed with atypical endometrial hyperplasia (AEH) and endometrioid carcinoma G1 without myometrial invasion (G1EC). Particular attention was given to the extended administration and readministration of MPA for patients with persistent disease following initial treatment and those with recurrence.
Methods
We conducted a retrospective analysis of data from 79 patients who underwent daily oral MPA treatment between 2005 and 2024 at Nagoya University Hospital. Patient characteristics, treatment outcomes, factors contributing to recurrence, and post‐MPA therapy pregnancies were examined.
Results
MPA therapy achieved a remarkable complete response (CR) rate of 91.1%. The median time to achieve CR was 26.0 and 40.0 weeks for AEH and G1EC patients, respectively. Importantly, 27 patients (39.7%) attained CR after more than 6 months of treatment, including 8 patients (11.8%) who achieved CR after more than a year of treatment. The recurrence rates were 52.9% for AEH and 64.7% for G1EC. Twenty eight patients resumed MPA treatment, and 23 achieved second CR. Notably, recurrence was not associated with clinical factors such as age, body mass index, or post‐CR pregnancy. Among patients who attempted pregnancy after achieving CR, 22 live births were successfully achieved.
Conclusions
High‐dose oral MPA therapy demonstrated both safety and efficacy for preserving fertility in patients with AEH and G1EC, resulting in a high CR rate. MPA extension and readministration proved to be beneficial strategies for managing patients with recurrence and persistent disease following initial treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
ORCID-Profile: Satoshi Tamauchi, Kosuke Yoshida, Masato Yoshihara, Nobuhisa Yoshikawa, Kaoru Niimi, Hiroaki Kajiyama
Zitieren
APA
Tamauchi, S., Nakagawa, A., Yoshida, K., Yoshihara, M., Yokoi, A., Yoshikawa, N., Niimi, K., & Kajiyama, H. (2024). Update on the oncologic and obstetric outcomes of medroxyprogesterone acetate treatment for atypical endometrial hyperplasia and endometrial cancer. Journal of Obstetrics and Gynaecology Research, 50(9), 1614-1621. https://doi.org/10.1111/jog.16038
Vancouver
Tamauchi S, Nakagawa A, Yoshida K, Yoshihara M, Yokoi A, Yoshikawa N, et al. Update on the oncologic and obstetric outcomes of medroxyprogesterone acetate treatment for atypical endometrial hyperplasia and endometrial cancer. Journal of Obstetrics and Gynaecology Research. 2024;50(9):1614-1621. doi:10.1111/jog.16038
BibTeX
@article{Tamauchi2024,
author = {Tamauchi, Satoshi and Nakagawa, Atsushi and Yoshida, Kosuke and Yoshihara, Masato and Yokoi, Akira and Yoshikawa, Nobuhisa and Niimi, Kaoru and Kajiyama, Hiroaki},
title = {Update on the oncologic and obstetric outcomes of medroxyprogesterone acetate treatment for atypical endometrial hyperplasia and endometrial cancer},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2024},
volume = {50},
number = {9},
pages = {1614--1621},
doi = {10.1111/jog.16038}
}
EUVIMED